The U.S. Food and Drug Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy. “Mantle cell lymphoma is a particularly aggressive cancer,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.
Bill Gates, Co-chair and Trustee of the Bill & Melinda Gates Foundation, and Francis Collins, Director of the National Institutes of Health (NIH), hold a live symposium at ASHG - American Society of Human Genetics to address global health and genomics.
The deadliest malaria parasite needs two proteins to infect red blood cells and exit the cells after it multiplies, a finding that may provide researchers with potential new targets for drug development, according to researchers funded by the National Institutes of Health. Their study appears in the latest issue of Science.
A set of indicators will assist European Union (EU) Member States to assess their progress in reducing the use of antimicrobials and combatting antimicrobial resistance. These indicators have been established by the European Food Safety Authority, the European Medicines Agency and the European Centre for Disease Prevention and Control, following a request from the European Commission.
Trabectedin (Yondelis*) provides a long term clinical benefit to patients with soft tissue sarcoma in second line treatment. This is the conclusions that appears in the scientific magazine 'Anti-cancer Drugs' i that has published the positive results of PharmaMar´s (MSE:PHM) observational, Y-IMAGE Phase IV study that evaluated the clinical practice of Yondelis* in patients with soft tissue sarcoma in European countries.
Novel smartphone and tablet applications (apps) for atrial fibrillation patients and healthcare professionals have been launched by heart experts. The objectives and design of the apps are outlined in a paper published online today in EP Europace,1 with a summary published in the European Heart Journal.2
The U.S. Food and Drug Administration approved a new treatment option for patients who have been diagnosed with moderate to severe central sleep apnea. The Remedē System is an implantable device that stimulates a nerve located in the chest that is responsible for sending signals to the diaphragm to stimulate breathing.
Preparedness in the face of major disease outbreaks can save thousands of lives: Rapid deployment of effective diagnostics, treatments, and vaccines may even stop the disease from potentially exploding into a pandemic.